GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)
Trial ID or NCT#
NCT04196413
Status
RECRUITING
Purpose
The primary purpose of this study is to test whether GD2-CAR T cells can be successfully made from immune cells collected from children and young adults with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.
Official Title
Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor (CAR) T Cells (GD2CART) for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG)
Eligibility Criteria
Ages Eligible for Study: 2 Years to 60 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Exclusion Criteria:
Investigator(s)
Michelle Monje
Paul Graham Fisher, MD
Neuro-oncologist,
Pediatric neurologist
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Sonia Partap
Kara Davis
Crystal Mackall
Laura Prolo
Associate Professor of Neurosurgery and, by courtesy, of Neurology (Pediatric Neurology)
Lindsey Rasmussen
Timothy Thomas Cornell
Sneha Ramakrishna
Katherine Jane Ryan
Contact us to find out if this trial is right for you.
Contact
GD2CART@stanfordchildrens.org
650-497-7533
View on